REG - Oncimmune Hldngs PLC - Notice of Half Year Results

Oncimmune HoldingsAnnouncement

25/01/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210125:nRSY6751Ma&default-theme=true

RNS Number : 6751M  Oncimmune Holdings PLC  25 January 2021

25 January 2021

 

Oncimmune Holdings plc

 

("Oncimmune" or the "Company")

 

Notice of Half Year Results

 

Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics
group, will be announcing its half year results for the six months ended 30
November 2020 on Monday, 15 February 2021.

 

Adam Hill, Chief Executive Officer, together with Matthew Hall, Chief
Financial Officer, will host a presentation and conference call for analysts
at 11:30am GMT on the day of the results.

 

For conference call details please contact Alexander Davis of FTI Consulting
at Alexander.Davis@fticonsulting.com
(mailto:Alexander.Davis@fticonsulting.com) or 020 3727 1000.

 

The management team will also host on Investor Meet Company a live
presentation of the results on Monday, 15 February 2021 at 16:30 GMT.

 

•     The online presentation will be open to all existing shareholders
and potential new investors.

 

•     Questions can be submitted before the event via your Investor Meet
Company dashboard or at any time during the live presentation via the "Ask a
Question" function. Responses to the Q&A will be published at the earliest
opportunity on the Investor Meet Company platform.

 

•     Investor feedback can also be submitted directly to management
immediately following the event.

 

Access to Investor Meet Company is free and interested parties can register to
attend the presentation via the following link:
https://www.investormeetcompany.com/oncimmune-holdings-plc/register-investor
(https://www.investormeetcompany.com/oncimmune-holdings-plc/register-investor)

 

Attendees who have already registered on the Investor Meet Company platform to
meet the Company will automatically receive an invitation to the presentation.

 

For further information:

 

Oncimmune Holdings plc

Adam Hill, Chief Executive Officer

Matthew Hall, Chief Financial Officer

contact@oncimmune.co.uk (mailto:contact@oncimmune.co.uk)

 

Zeus Capital Limited (Nominated Adviser and Joint Broker)

Andrew Jones, Daniel Harris, Victoria Ayton

+44 (0)20 3829 5000

 

N+1 Singer (Joint Broker)

Aubrey Powell, Harry Gooden, Iqra Amin, James Fischer

+44 (0)20 7496 3000

 

WG Partners (Joint Broker)

David Wilson, Chris Lee

+44 (0)203 705 9321

 

Media enquiries:

FTI Consulting

Ben Atwell, Michael Trace, Alex Davis

Oncimmune@fticonsulting.com (mailto:Oncimmune@fticonsulting.com)

+44 (0)20 3727 1000

 

About Oncimmune

 

Our intimate understanding of the human immune system enables us to harness
its sophisticated response to disease to detect cancer earlier and to support
the development of better therapies. The key to improving cancer survival is
early detection and better selection for therapy. As a company, we are driven
by our passion to improve cancer survival and to give people extra time.

 

Oncimmune is a leading immunodiagnostics developer, primarily focused on the
growing fields of immuno-oncology, autoimmune disease and infectious diseases.
Oncimmune has a diversified and growing revenue from its portfolio of
diagnostic products to detect early-stage cancer and a contract discovery and
development service-based platform, delivering actionable insights into
therapies to its pharmaceutical and biotech partners.

 

Oncimmune's ImmunoINSIGHTS platform enables life-science organisations to
optimise drug development and delivery, leading to more effective targeted as
well as safer treatments for patients. Oncimmune's immunodiagnostic
technology, EarlyCDT, can detect and help identify cancer on average four
years earlier than standard clinical diagnosis. Our lead diagnostic test,
EarlyCDT Lung, targets a vast market estimated to grow to £3.8bn by 2024.
With over 200,000 tests already performed for patients worldwide and its use
being supported by peer reviewed data in over 12,000 patients, we are poised
to become an integral component of future lung cancer detection programmes,
globally.

 

Oncimmune, headquartered at its laboratory facility in Nottingham, UK, has a
discovery research centre in Dortmund, Germany and a partner representative
office in Shanghai, China.

 

For more information, visit www.oncimmune.com (http://www.oncimmune.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORDZGZMRZDGMZM